Vistin Pharma ASA - Asset Resilience Ratio

Latest as of March 2025: 3.08%

Vistin Pharma ASA (VISTN) has an Asset Resilience Ratio of 3.08% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Vistin Pharma ASA (VISTN) strategic investment index to assess the company's strategic physical and investment asset allocation.

Liquid Assets

Nkr12.67 Million

≈ $1.33 Million USD Cash + Short-term Investments

Total Assets

Nkr411.55 Million

≈ $43.31 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2023)

This chart shows how Vistin Pharma ASA's Asset Resilience Ratio has changed over time. See Vistin Pharma ASA balance sheet independence to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Vistin Pharma ASA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see VISTN market cap.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Nkr12.67 Million	3.08%
Short-term Investments	Nkr0.00	0%
Total Liquid Assets	Nkr12.67 Million	3.08%

Asset Resilience Insights

Limited Liquidity: Vistin Pharma ASA maintains only 3.08% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Vistin Pharma ASA Industry Peers by Asset Resilience Ratio

Compare Vistin Pharma ASA's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ) ST:SOBI	Drug Manufacturers - Specialty & Generic	1.54%
Aurobindo Pharma Limited NSE:AUROPHARMA	Drug Manufacturers - Specialty & Generic	1.28%
Shijiazhuang Yiling Pharmaceutical Co Ltd SHE:002603	Drug Manufacturers - Specialty & Generic	11.60%
Shandong Buchang Pharmaceuticals Co Ltd SHG:603858	Drug Manufacturers - Specialty & Generic	3.47%
Tianjin Chase Sun Pharmaceutical Co Ltd SHE:300026	Drug Manufacturers - Specialty & Generic	-0.89%
Zhejiang Hisoar Pharmaceutical Co Ltd SHE:002099	Drug Manufacturers - Specialty & Generic	0.20%
Xeris Pharmaceuticals Inc NASDAQ:XERS	Drug Manufacturers - Specialty & Generic	0.00%
Procter & Gamble Health Limited NSE:PGHL	Drug Manufacturers - Specialty & Generic	33.01%

Annual Asset Resilience Ratio for Vistin Pharma ASA (2016–2023)

The table below shows the annual Asset Resilience Ratio data for Vistin Pharma ASA.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2023-12-31	6.50%	Nkr26.20 Million ≈ $2.76 Million	Nkr403.40 Million ≈ $42.45 Million	+6.14pp
2022-12-31	0.35%	Nkr1.44 Million ≈ $151.00K	Nkr407.21 Million ≈ $42.85 Million	-23.58pp
2020-12-31	23.93%	Nkr77.04 Million ≈ $8.11 Million	Nkr321.92 Million ≈ $33.87 Million	-12.75pp
2019-12-31	36.68%	Nkr184.91 Million ≈ $19.46 Million	Nkr504.17 Million ≈ $53.05 Million	-10.03pp
2018-12-31	46.71%	Nkr233.58 Million ≈ $24.58 Million	Nkr500.06 Million ≈ $52.62 Million	+14.71pp
2016-12-31	32.00%	Nkr89.44 Million ≈ $9.41 Million	Nkr279.52 Million ≈ $29.41 Million	--

pp = percentage points

About Vistin Pharma ASA

OL:VISTN Norway Drug Manufacturers - Specialty & Generic

Market Cap

$95.66 Million

Nkr909.06 Million NOK

Market Cap Rank

#19438 Global

#175 in Norway

Share Price

Nkr20.50

Change (1 day)

-0.97%

52-Week Range

Nkr19.70 - Nkr25.30

All Time High

Nkr28.06